Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Elvis Presley's Infamous Pantera Shooting - 2Vote In favor of Your Favored Pet Consideration Administration
- 3Ocean side Objections: Staggering Waterfront Breaks
- 4What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- 5Eleven Creations And Developments That Steered History
- The Manual for Electric Vehicles that will be hot dealers in 2023
- Remain Fit and Sound with These Exercise Fundamentals
- Tech Patterns: Contraptions That Will Shape What's in store
- Nations for Rock Climbing
- Melodic Combination d: A Survey of \Unrecorded Music Energy\ Show
- What to know about MIT professor Nuno Loureiro and the investigation into his shooting
- Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- ‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
